EZETEMIBE COMBINATION THERAPY + HIGH INTENSITYSTATIN

Journal - Ezetemibe combination therapy vs High intensity statin

1. BACKGROUND 30% to 60% of patients with diabetes have dyslipidemia recent guidelines aim to reduce LDL-C, and recommend using moderate-intensity statins for the primary prevention of ASCVD in patients with diabetes aged 40-75 years; high-intensity statins should be considered for multiple risk factors. all previous studies on the effectiveness of combination therapy of statin and ezetimibe were secondary prevention studies of CVD There has been no randomized controlled trial study comparing the primary preventive effects of statin monotherapy and combination therapy of statin and ezetimibe on CVD.

2. AIM to compare the primary prevention effect of myocardial infarction (MI), stroke, and all-cause death between combination therapy of low-intensity statins and ezetimibe (L-S/E) or moderate-intensity statins and ezetimibe (M-S/E) and high-intensity statin (H-S) monotherapy in Korean patients with diabetes.

3. Materials and Methods between January 2014 and December 2019

4. IMPROVE-IT trial, the combination therapy of simvastatin 40 mg and ezetimibe 10 mg improved cardiovascular outcomes compared with simvastatin 40 mg alone in patients with acute coronary syndrome RACING trial, moderate-intensity statin with ezetimibe combination therapy ( rosuvastatin 10 mg and ezetimibe 10 mg ) was noninferior to high-intensity statin monotherapy (rosuvastatin 20 mg) for the 3-year composite outcomes of cardiovascular death, major cardiovascular events, or nonfatal stroke in patients with ASCVD. Adding ezetimibe to a moderate-intensity statin in Korean patients with diabetes, a high-risk group for ASCVD, has a greater LDL-lowering effect and a greater primary prevention effect on the composite outcome of MI, stroke, and all-cause death than that of high-intensity statin monotherapy.